227 related articles for article (PubMed ID: 29660851)
1. Temporal trends in management and outcomes of testicular cancer: A population-based study.
Leveridge MJ; Siemens DR; Brennan K; Izard JP; Karim S; An H; Mackillop WJ; Booth CM
Cancer; 2018 Jul; 124(13):2724-2732. PubMed ID: 29660851
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.
Mazzone E; Mistretta FA; Knipper S; Tian Z; Palumbo C; Gandaglia G; Soulieres D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2019 Dec; 17(6):e1153-e1162. PubMed ID: 31515197
[TBL] [Abstract][Full Text] [Related]
3. Treatment of a population based sample of men diagnosed with testicular cancer in the United States.
Osswald M; Harlan LC; Penson D; Stevens JL; Clegg LX
Urol Oncol; 2009; 27(6):604-10. PubMed ID: 18799329
[TBL] [Abstract][Full Text] [Related]
4. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
Tabakin AL; Shinder BM; Kim S; Rivera-Nunez Z; Polotti CF; Modi PK; Sterling JA; Farber NJ; Radadia KD; Parikh RR; Kim IY; Saraiya B; Mayer TM; Singer EA; Jang TL
Clin Genitourin Cancer; 2020 Apr; 18(2):e194-e201. PubMed ID: 31818649
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.
Patel HD; Joice GA; Schwen ZR; Semerjian A; Alam R; Srivastava A; Allaf ME; Pierorazio PM
World J Urol; 2018 Jan; 36(1):73-78. PubMed ID: 29026972
[TBL] [Abstract][Full Text] [Related]
6. Contemporary Trends in Presentation and Management of Spermatocytic Seminoma.
Patel PM; Patel HD; Koehne EL; Doshi C; Belshoff A; Seffren CM; Baker M; Gorbonos A; Gupta G
Urology; 2020 Dec; 146():177-182. PubMed ID: 33049234
[TBL] [Abstract][Full Text] [Related]
7. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
8. Delivery of chemotherapy for testicular cancer in routine practice: A population-based study.
Karim S; Wei X; Leveridge MJ; Siemens DR; Robinson AG; Bedard PL; Booth CM
Urol Oncol; 2019 Mar; 37(3):183.e17-183.e24. PubMed ID: 30478011
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
11. Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors.
Heidenreich A; Paffenholz P; Nestler T; Pfister D; Daneshmand S
Curr Opin Urol; 2020 Mar; 30(2):251-257. PubMed ID: 31972635
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
13. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
14. Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion.
Avulova S; Allen C; Morgans A; Moses KA
Urol Oncol; 2018 Jul; 36(7):342.e1-342.e6. PubMed ID: 29754945
[TBL] [Abstract][Full Text] [Related]
15. Early-stage testis cancer.
Foster RS
Curr Treat Options Oncol; 2001 Oct; 2(5):413-9. PubMed ID: 12057104
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.
Stokes W; Amini A; Maroni PD; Kessler ER; Stokes C; Cost CR; Greffe BS; Garrington TP; Liu AK; Cost NG
J Pediatr Urol; 2017 Aug; 13(4):386.e1-386.e7. PubMed ID: 28153774
[TBL] [Abstract][Full Text] [Related]
17. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
18. Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
Powles T
Hematol Oncol Clin North Am; 2011 Jun; 25(3):517-27,viii. PubMed ID: 21570606
[TBL] [Abstract][Full Text] [Related]
19. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
20. Management of stage I testicular germ cell tumours.
Chovanec M; Hanna N; Cary KC; Einhorn L; Albany C
Nat Rev Urol; 2016 Nov; 13(11):663-673. PubMed ID: 27618772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
